DRUGS MADE IN AMERICA ACQUISITION CORP.
DMAA DMAAR DMAAUCIK 0002028614
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
$7.7M
+2,222.8% YoY
Q1 May 2026
EPS Diluted (TTM)
−$0.03
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$14.89K
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
24.28M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.